Antibody-Drug Conjugates

CMC Considerations for Commercial-Ready ADC Manufacturing Processes to Enable Accelerated Timelines

On Wednesday, May 1, 2019, at the CPhI Theater, Courtney Morgret, PhD, senior scientist at ABBVIE, shared some key chemistry manufacturing and controls (CMC) considerations for antibody-drug conjugate products. The objective is to use prior-knowledge to move the product to clinic quickly. She discussed manufacturing strategy including contract development and manufacturing organization selection, regulatory affairs communication experience, and process characterization and analytical understanding. Fill out the form below to watch this presentation now.

Benefits of Using a CMO for Antibody Drug Conjugates

This podcast features: Cynthia Wooge, PhD, Global Strategic Marketing, SAFC This podcast was recorded based on a presentation given at the 2014 BioProcess Theater which took place at the 2014 BIO International Convention, June 23-26, 2014. The BioProcess Theater, a 50-seat amphitheater located on the exhibition floor at the heart of the BioProcess Zone, provided attendees with daily, complimentary opportunities to listen, learn, and interact with leading experts as they presented, discussed and debated the latest business and scientific trends…

The Future Directions of ADC Development

This podcast features: David Rabuka, PhD, President, Chief Scientific Officer, Founder, Redwood Bioscience This podcast was recorded based on a presentation given at the 2014 BioProcess Theater which took place at the 2014 BIO International Convention, June 23-26, 2014. The BioProcess Theater, a 50-seat amphitheater located on the exhibition floor at the heart of the BioProcess Zone, provided attendees with daily, complimentary opportunities to listen, learn, and interact with leading experts as they presented, discussed and debated the latest business…